[go: up one dir, main page]

PE20081402A1 - Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura - Google Patents

Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura

Info

Publication number
PE20081402A1
PE20081402A1 PE2007001794A PE2007001794A PE20081402A1 PE 20081402 A1 PE20081402 A1 PE 20081402A1 PE 2007001794 A PE2007001794 A PE 2007001794A PE 2007001794 A PE2007001794 A PE 2007001794A PE 20081402 A1 PE20081402 A1 PE 20081402A1
Authority
PE
Peru
Prior art keywords
thimo
depressors
processes
manufacturing
pharmaceutically acceptable
Prior art date
Application number
PE2007001794A
Other languages
English (en)
Inventor
Tim Tam
Zemba Blaise N
Regis Leung-Toung
Yinsheng Wang
Yanquing Zhao
Lily Yu
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of PE20081402A1 publication Critical patent/PE20081402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UNA SAL DE D-ISOGLUTAMIL-D-TRIPTOFANO (H-D-iGLU-D-Trp-OH O TIMODEPRESOR) DE FORMULA (I), DONDE M ES POTASIO O LITIO, EL CUAL ES UN DIPEPTIDO HEMOREGULADOR SINTETICO. DICHAS SALES SE ENCUENTRAN TAMBIEN EN FORMA CRISTALINA, DONDE LA SAL DE POTASIO DEL COMPUESTO EN FORMA CRISTALINA PRESENTA PICOS EN UN PATRON DE DIFRACCION DE RAYOS X EN POLVO CON VALORES DE 2-THETA: 9,91, 14,84, 15,81, 18,97, 19,76, 24,04, 24,36, 24,82, 25,48, 27,49, 28,42, 30,82, 31,28, 31,69, 32,17, 34,35, 35,81 Y 36,96 Y LA SAL DE LITIO DEL COMPUESTO PRESENTA PICOS DE 13,57, 15,53, 18,71, 20,11, 23,34, 24,1, 25,09, 27,31, 27,72, 28,39, 29,31, 30,19, 31,21, 32,06, 33,62 Y 37,41. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION
PE2007001794A 2006-12-19 2007-12-14 Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura PE20081402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002571645A CA2571645A1 (en) 2006-12-19 2006-12-19 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture

Publications (1)

Publication Number Publication Date
PE20081402A1 true PE20081402A1 (es) 2008-11-16

Family

ID=39535926

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000979A PE20121642A1 (es) 2006-12-19 2007-12-14 Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
PE2007001794A PE20081402A1 (es) 2006-12-19 2007-12-14 Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000979A PE20121642A1 (es) 2006-12-19 2007-12-14 Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura

Country Status (14)

Country Link
US (2) US8138221B2 (es)
EP (1) EP2121729A4 (es)
KR (1) KR20090108034A (es)
CN (2) CN103554004A (es)
AU (1) AU2007335212B2 (es)
CA (2) CA2571645A1 (es)
CL (1) CL2007003680A1 (es)
MX (1) MX2009006673A (es)
PE (2) PE20121642A1 (es)
RU (1) RU2536685C2 (es)
TW (1) TWI406872B (es)
UA (1) UA106580C2 (es)
UY (1) UY30798A1 (es)
WO (1) WO2008074128A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579119C (en) 2007-02-16 2013-03-05 Apotex Technologies Inc. Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
RU2634258C1 (ru) * 2016-11-08 2017-10-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Наполнитель для капсульного ингалятора
RU2703991C1 (ru) * 2019-02-12 2019-10-23 Акционерное общество "Медико-биологический научно-производственный комплекс "Цитомед" (АО "МБНПК "Цитомед") Способ получения мононатриевой соли изоглутамил-триптофана

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3238118A1 (de) * 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen
GB2152031B (en) * 1984-01-10 1987-07-22 Mitsui Toatsu Chemicals Separating l-tryptophan from fermentation broth
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
RU2107691C1 (ru) * 1995-03-02 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US6103699A (en) * 1996-06-07 2000-08-15 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
DE19540788A1 (de) * 1995-11-02 1997-05-07 Degussa Verwendung von wässrigen L-Tryptophan- und/oder L-Threonin-Salzlösungen
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
IL120923A0 (en) 1997-05-27 1997-09-30 Amylum Nv A combined process for the production of lysine and its salts and of a further weak acid and a salt thereof
EP2046778B1 (en) * 2006-08-04 2013-12-04 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
CA2569204A1 (en) * 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan

Also Published As

Publication number Publication date
TWI406872B (zh) 2013-09-01
US8735602B2 (en) 2014-05-27
UY30798A1 (es) 2008-07-03
KR20090108034A (ko) 2009-10-14
US20130072692A1 (en) 2013-03-21
MX2009006673A (es) 2009-11-02
US20100056803A1 (en) 2010-03-04
RU2536685C2 (ru) 2014-12-27
CL2007003680A1 (es) 2008-03-14
RU2009127795A (ru) 2011-01-27
CA2571645A1 (en) 2008-06-19
EP2121729A4 (en) 2013-07-31
CN101611050A (zh) 2009-12-23
EP2121729A1 (en) 2009-11-25
CN103554004A (zh) 2014-02-05
CN101611050B (zh) 2013-10-30
TW200833708A (en) 2008-08-16
WO2008074128A1 (en) 2008-06-26
PE20121642A1 (es) 2012-12-16
AU2007335212A1 (en) 2008-06-26
US8138221B2 (en) 2012-03-20
CA2673421A1 (en) 2008-06-26
AU2007335212B2 (en) 2013-09-05
UA106580C2 (uk) 2014-09-25

Similar Documents

Publication Publication Date Title
AR112669A2 (es) Compuestos inhibidores del cotransportador de sodio y glucosa 2 y compuestos útiles para su preparación
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ME02558B (me) Inhibitori replikacije virusa gripa
RU2013109393A (ru) Безилатная соль ингибитора втк
CY1117021T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης
PE20050761A1 (es) Polimorfo cristalino de una sal de bisulfato como antagonista del receptor de trombina
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20110388A1 (es) Formas cristalinas de un derivado de peptido como inhibidores de hcv
JP2006298933A5 (es)
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
WO2009083940A3 (en) Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts
MY151295A (en) Pyrimidyl indoline compound
EA201600088A1 (ru) Парентеральное введение тапентадола
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
AR084862A1 (es) Formas solidas de inhibidor de girasa (r) 1-etil-3-[5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
AR053119A1 (es) Forma cristalina b del monohidrato de la sal monosodica del acido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1,1-difosfonico (ibandronato)
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
PE20070548A1 (es) Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
AR074592A1 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina, procesos e intermediario para su sintesis y su uso en el tratamiento de una enfermedad mediada por un antagonista de los receptores mu opioides.

Legal Events

Date Code Title Description
FC Refusal